Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28353554 | 0.89 | EPHX2 (0.39) | EPHX2MDM4TP53DCUN1D1CASP3 | |
| SCHEMBL29555021 | 0.89 | EPHX2 (0.39) | EPHX2MDM4TP53DCUN1D1CASP3 | |
| SCHEMBL20522895 | 0.89 | MDM4 (0.46) | MDM4TP53CASP3AKR1B1 | |
| SCHEMBL20522894 | 0.89 | MDM4 (0.46) | MDM4TP53CASP3AKR1B1 | |
| SCHEMBL30714788 | 0.89 | MDM4 (0.43) | EPHX2MDM4TP53CASP3KMT2A | |
| SCHEMBL20526665 | 0.79 | MDM2 (0.49) | EPHX2MDM4TP53CASP3 | |
| SCHEMBL20526668 | 0.79 | MDM2 (0.49) | EPHX2MDM4TP53CASP3 | |
| SCHEMBL20526602 | 0.77 | MDM4 (0.46) | MDM4TP53CASP3 | |
| SCHEMBL20526600 | 0.77 | MDM4 (0.46) | MDM4TP53CASP3 | |
| SCHEMBL32676400 | 0.77 | MDM2 (0.51) | MDM4TP53CASP3MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012467-B2 | Small molecule DCN1 inhibitors and therapeutic methods using the same | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-18 | — | — | US | disclosed |
| EP-3609876-B1 | COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012467-B2 | Small molecule DCN1 inhibitors and therapeutic methods using the same | DCUN1D2, CLN6, CAPNS1 | EPHX2 3934/4885MDM4 4319/4885TP53 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.